Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database
The objectives were to describe treatment sequences for advanced colorectal cancer (CRC), use of second-line FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) plus antiangiogenic drug (bevacizumab, ramucirumab, aflibercept beta) therapy, and the factors associated with the duration of antitumor drug...
Gespeichert in:
| Veröffentlicht in: | PloS one 2021-02, Vol.16 (2), p.e0246160-e0246160 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0246160 |
|---|---|
| container_issue | 2 |
| container_start_page | e0246160 |
| container_title | PloS one |
| container_volume | 16 |
| creator | Shinozaki, Eiji Makiyama, Akitaka Kagawa, Yoshinori Satake, Hironaga Tanizawa, Yoshinori Cai, Zhihong Piao, Yongzhe |
| description | The objectives were to describe treatment sequences for advanced colorectal cancer (CRC), use of second-line FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) plus antiangiogenic drug (bevacizumab, ramucirumab, aflibercept beta) therapy, and the factors associated with the duration of antitumor drug treatment from second-line antiangiogenic therapy in Japan. This retrospective observational study was conducted using a Japanese hospital-based administrative database. Patients were enrolled if they started adjuvant therapy (and presumably experienced early recurrence) or first-line treatment for advanced CRC between May 2016 and July 2019, and were analysed until September 2019. Factors associated with overall treatment duration from second-line treatment with FOLFIRI plus antiangiogenic drugs were explored with multivariate Cox regression analysis. The most common first-line treatments were FOLFOX (leucovorin, 5-fluorouracil, oxaliplatin) or CAPOX (capecitabine, oxaliplatin) with bevacizumab (presumed RAS-mutant CRC) and FOLFOX with panitumumab (presumed RAS-wild type CRC). The most common second-line treatments were FOLFIRI-based. Many patients did not transition to subsequent lines of therapy. For second-line treatment, antiangiogenic drugs were prescribed more often for patients with presumed RAS-mutant CRC, right-sided CRC, and independent activities of daily living (ADL). The median duration of second-line FOLFIRI plus antiangiogenic drug treatment was 4.5 months; 66.2% of patients transitioned to third-line therapy. Low body mass index and not fully independent ADL were significantly associated with shorter overall duration of antitumor drug treatment from second-line therapy. Left-sided CRC, presumed RAS-wild type CRC, previous use of oral fluoropyrimidines and use of proteinuria qualitative tests, antihypertensives, or anticholinergics during second-line therapy were significantly associated with longer treatment. Treatment of advanced CRC in Japan is consistent with both international and Japanese guidelines, but transition rates to subsequent therapies need improvement. In addition to antitumor drug treatment, better ADL, higher body mass index, management of hypertension, and proteinuria tests were associated with continuation of sequential therapy that included antiangiogenic drugs. |
| doi_str_mv | 10.1371/journal.pone.0246160 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2487424657</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A651160888</galeid><doaj_id>oai_doaj_org_article_8a6b6f8616b04dc1a6995cdd76416fb3</doaj_id><sourcerecordid>A651160888</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-a063451a34783dff93895b37d87771850169b140a298eca382240fc3598b6bd83</originalsourceid><addsrcrecordid>eNqNk8Fu1DAQhiMEoqXwBggsISE47OLEie1wQFpVFBZVqlQKV2tiO1lXWXtrOwt9Ql4Lp5tWXdQDysHR-Jt_ZjwzWfYyx_OcsPzDpRu8hX6-cVbPcVHSnOJH2WFek2JGC0we3_s_yJ6FcIlxRTilT7MDQqqK4ro6zP5ceA1xrW1EQV8N2kodkGvRBqJJxoB-mbhCoLaQbhSSrndeywg9kqPFI7AKDUGPPkFLZ9WsN1ajk7PTk-X5cnK30YDtjOu0NRIpP3QBGYu-wQbsR7RAXkfvwiYJm22SaoL225SAS_WhEAd1nUIY2yWhlMraWBOihxtWQYQGgn6ePWmhD_rFdB5lP04-Xxx_nZ2efVkeL05nktZFnAGmpKxyICXjRLVtTXhdNYQpzhjLeYVzWjd5iaGouZZAeFGUuJWkqnlDG8XJUfZ6p7vpXRBTD4IoSs7K1IOKJWK5I5SDS7HxZg3-Wjgw4sbgfCfARyN7LTjQhrY8da7BpZI50LqupFKMljltG5K0Pk3RhmatlUwd8dDvie7fWLMSndsKxhnGrE4C7yYB71J3QxRrE6Tue7DaDbu8WckoLhL65h_04eomqoNUgLGtS3HlKCoWtMrTDHI-vtL8ASp9Sq9NGhLdmmTfc3i_55CYqH_HDoYQxPL7-f-zZz_32bf32JWGPq6C64dxtsI-WO5AmQYxeN3ePXKOxbhvt68hxn0T074lt1f3G3TndLtg5C_25Cis</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2487424657</pqid></control><display><type>article</type><title>Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Shinozaki, Eiji ; Makiyama, Akitaka ; Kagawa, Yoshinori ; Satake, Hironaga ; Tanizawa, Yoshinori ; Cai, Zhihong ; Piao, Yongzhe</creator><contributor>Nagasaka, Takeshi</contributor><creatorcontrib>Shinozaki, Eiji ; Makiyama, Akitaka ; Kagawa, Yoshinori ; Satake, Hironaga ; Tanizawa, Yoshinori ; Cai, Zhihong ; Piao, Yongzhe ; Nagasaka, Takeshi</creatorcontrib><description>The objectives were to describe treatment sequences for advanced colorectal cancer (CRC), use of second-line FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) plus antiangiogenic drug (bevacizumab, ramucirumab, aflibercept beta) therapy, and the factors associated with the duration of antitumor drug treatment from second-line antiangiogenic therapy in Japan. This retrospective observational study was conducted using a Japanese hospital-based administrative database. Patients were enrolled if they started adjuvant therapy (and presumably experienced early recurrence) or first-line treatment for advanced CRC between May 2016 and July 2019, and were analysed until September 2019. Factors associated with overall treatment duration from second-line treatment with FOLFIRI plus antiangiogenic drugs were explored with multivariate Cox regression analysis. The most common first-line treatments were FOLFOX (leucovorin, 5-fluorouracil, oxaliplatin) or CAPOX (capecitabine, oxaliplatin) with bevacizumab (presumed RAS-mutant CRC) and FOLFOX with panitumumab (presumed RAS-wild type CRC). The most common second-line treatments were FOLFIRI-based. Many patients did not transition to subsequent lines of therapy. For second-line treatment, antiangiogenic drugs were prescribed more often for patients with presumed RAS-mutant CRC, right-sided CRC, and independent activities of daily living (ADL). The median duration of second-line FOLFIRI plus antiangiogenic drug treatment was 4.5 months; 66.2% of patients transitioned to third-line therapy. Low body mass index and not fully independent ADL were significantly associated with shorter overall duration of antitumor drug treatment from second-line therapy. Left-sided CRC, presumed RAS-wild type CRC, previous use of oral fluoropyrimidines and use of proteinuria qualitative tests, antihypertensives, or anticholinergics during second-line therapy were significantly associated with longer treatment. Treatment of advanced CRC in Japan is consistent with both international and Japanese guidelines, but transition rates to subsequent therapies need improvement. In addition to antitumor drug treatment, better ADL, higher body mass index, management of hypertension, and proteinuria tests were associated with continuation of sequential therapy that included antiangiogenic drugs.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0246160</identifier><identifier>PMID: 33556095</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Angiogenesis inhibitors ; Antiangiogenic agents ; Antiangiogenics ; Biology and Life Sciences ; Cancer ; Cancer therapies ; Chemotherapy ; Clinical medicine ; Clinical trials ; Colorectal cancer ; Colorectal carcinoma ; Disease ; Drug therapy ; Editing ; Epidermal growth factor receptors ; Ethics ; Fluorouracil ; Funding ; Gastroenterology ; Health care facilities ; Health services ; Homology ; Hospitals ; Leucovorin ; Medical research ; Medicine ; Medicine and Health Sciences ; Methodology ; Mutation ; Observational studies ; Patients ; Population ; Prescription drugs ; Sarcoma ; Surgery ; Visualization</subject><ispartof>PloS one, 2021-02, Vol.16 (2), p.e0246160-e0246160</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 Shinozaki et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Shinozaki et al 2021 Shinozaki et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-a063451a34783dff93895b37d87771850169b140a298eca382240fc3598b6bd83</citedby><cites>FETCH-LOGICAL-c692t-a063451a34783dff93895b37d87771850169b140a298eca382240fc3598b6bd83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870079/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870079/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,2096,2915,23847,27905,27906,53772,53774,79349,79350</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33556095$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Nagasaka, Takeshi</contributor><creatorcontrib>Shinozaki, Eiji</creatorcontrib><creatorcontrib>Makiyama, Akitaka</creatorcontrib><creatorcontrib>Kagawa, Yoshinori</creatorcontrib><creatorcontrib>Satake, Hironaga</creatorcontrib><creatorcontrib>Tanizawa, Yoshinori</creatorcontrib><creatorcontrib>Cai, Zhihong</creatorcontrib><creatorcontrib>Piao, Yongzhe</creatorcontrib><title>Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The objectives were to describe treatment sequences for advanced colorectal cancer (CRC), use of second-line FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) plus antiangiogenic drug (bevacizumab, ramucirumab, aflibercept beta) therapy, and the factors associated with the duration of antitumor drug treatment from second-line antiangiogenic therapy in Japan. This retrospective observational study was conducted using a Japanese hospital-based administrative database. Patients were enrolled if they started adjuvant therapy (and presumably experienced early recurrence) or first-line treatment for advanced CRC between May 2016 and July 2019, and were analysed until September 2019. Factors associated with overall treatment duration from second-line treatment with FOLFIRI plus antiangiogenic drugs were explored with multivariate Cox regression analysis. The most common first-line treatments were FOLFOX (leucovorin, 5-fluorouracil, oxaliplatin) or CAPOX (capecitabine, oxaliplatin) with bevacizumab (presumed RAS-mutant CRC) and FOLFOX with panitumumab (presumed RAS-wild type CRC). The most common second-line treatments were FOLFIRI-based. Many patients did not transition to subsequent lines of therapy. For second-line treatment, antiangiogenic drugs were prescribed more often for patients with presumed RAS-mutant CRC, right-sided CRC, and independent activities of daily living (ADL). The median duration of second-line FOLFIRI plus antiangiogenic drug treatment was 4.5 months; 66.2% of patients transitioned to third-line therapy. Low body mass index and not fully independent ADL were significantly associated with shorter overall duration of antitumor drug treatment from second-line therapy. Left-sided CRC, presumed RAS-wild type CRC, previous use of oral fluoropyrimidines and use of proteinuria qualitative tests, antihypertensives, or anticholinergics during second-line therapy were significantly associated with longer treatment. Treatment of advanced CRC in Japan is consistent with both international and Japanese guidelines, but transition rates to subsequent therapies need improvement. In addition to antitumor drug treatment, better ADL, higher body mass index, management of hypertension, and proteinuria tests were associated with continuation of sequential therapy that included antiangiogenic drugs.</description><subject>Angiogenesis inhibitors</subject><subject>Antiangiogenic agents</subject><subject>Antiangiogenics</subject><subject>Biology and Life Sciences</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Disease</subject><subject>Drug therapy</subject><subject>Editing</subject><subject>Epidermal growth factor receptors</subject><subject>Ethics</subject><subject>Fluorouracil</subject><subject>Funding</subject><subject>Gastroenterology</subject><subject>Health care facilities</subject><subject>Health services</subject><subject>Homology</subject><subject>Hospitals</subject><subject>Leucovorin</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Methodology</subject><subject>Mutation</subject><subject>Observational studies</subject><subject>Patients</subject><subject>Population</subject><subject>Prescription drugs</subject><subject>Sarcoma</subject><subject>Surgery</subject><subject>Visualization</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk8Fu1DAQhiMEoqXwBggsISE47OLEie1wQFpVFBZVqlQKV2tiO1lXWXtrOwt9Ql4Lp5tWXdQDysHR-Jt_ZjwzWfYyx_OcsPzDpRu8hX6-cVbPcVHSnOJH2WFek2JGC0we3_s_yJ6FcIlxRTilT7MDQqqK4ro6zP5ceA1xrW1EQV8N2kodkGvRBqJJxoB-mbhCoLaQbhSSrndeywg9kqPFI7AKDUGPPkFLZ9WsN1ajk7PTk-X5cnK30YDtjOu0NRIpP3QBGYu-wQbsR7RAXkfvwiYJm22SaoL225SAS_WhEAd1nUIY2yWhlMraWBOihxtWQYQGgn6ePWmhD_rFdB5lP04-Xxx_nZ2efVkeL05nktZFnAGmpKxyICXjRLVtTXhdNYQpzhjLeYVzWjd5iaGouZZAeFGUuJWkqnlDG8XJUfZ6p7vpXRBTD4IoSs7K1IOKJWK5I5SDS7HxZg3-Wjgw4sbgfCfARyN7LTjQhrY8da7BpZI50LqupFKMljltG5K0Pk3RhmatlUwd8dDvie7fWLMSndsKxhnGrE4C7yYB71J3QxRrE6Tue7DaDbu8WckoLhL65h_04eomqoNUgLGtS3HlKCoWtMrTDHI-vtL8ASp9Sq9NGhLdmmTfc3i_55CYqH_HDoYQxPL7-f-zZz_32bf32JWGPq6C64dxtsI-WO5AmQYxeN3ePXKOxbhvt68hxn0T074lt1f3G3TndLtg5C_25Cis</recordid><startdate>20210208</startdate><enddate>20210208</enddate><creator>Shinozaki, Eiji</creator><creator>Makiyama, Akitaka</creator><creator>Kagawa, Yoshinori</creator><creator>Satake, Hironaga</creator><creator>Tanizawa, Yoshinori</creator><creator>Cai, Zhihong</creator><creator>Piao, Yongzhe</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210208</creationdate><title>Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database</title><author>Shinozaki, Eiji ; Makiyama, Akitaka ; Kagawa, Yoshinori ; Satake, Hironaga ; Tanizawa, Yoshinori ; Cai, Zhihong ; Piao, Yongzhe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-a063451a34783dff93895b37d87771850169b140a298eca382240fc3598b6bd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Angiogenesis inhibitors</topic><topic>Antiangiogenic agents</topic><topic>Antiangiogenics</topic><topic>Biology and Life Sciences</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Disease</topic><topic>Drug therapy</topic><topic>Editing</topic><topic>Epidermal growth factor receptors</topic><topic>Ethics</topic><topic>Fluorouracil</topic><topic>Funding</topic><topic>Gastroenterology</topic><topic>Health care facilities</topic><topic>Health services</topic><topic>Homology</topic><topic>Hospitals</topic><topic>Leucovorin</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Methodology</topic><topic>Mutation</topic><topic>Observational studies</topic><topic>Patients</topic><topic>Population</topic><topic>Prescription drugs</topic><topic>Sarcoma</topic><topic>Surgery</topic><topic>Visualization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shinozaki, Eiji</creatorcontrib><creatorcontrib>Makiyama, Akitaka</creatorcontrib><creatorcontrib>Kagawa, Yoshinori</creatorcontrib><creatorcontrib>Satake, Hironaga</creatorcontrib><creatorcontrib>Tanizawa, Yoshinori</creatorcontrib><creatorcontrib>Cai, Zhihong</creatorcontrib><creatorcontrib>Piao, Yongzhe</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shinozaki, Eiji</au><au>Makiyama, Akitaka</au><au>Kagawa, Yoshinori</au><au>Satake, Hironaga</au><au>Tanizawa, Yoshinori</au><au>Cai, Zhihong</au><au>Piao, Yongzhe</au><au>Nagasaka, Takeshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2021-02-08</date><risdate>2021</risdate><volume>16</volume><issue>2</issue><spage>e0246160</spage><epage>e0246160</epage><pages>e0246160-e0246160</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The objectives were to describe treatment sequences for advanced colorectal cancer (CRC), use of second-line FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) plus antiangiogenic drug (bevacizumab, ramucirumab, aflibercept beta) therapy, and the factors associated with the duration of antitumor drug treatment from second-line antiangiogenic therapy in Japan. This retrospective observational study was conducted using a Japanese hospital-based administrative database. Patients were enrolled if they started adjuvant therapy (and presumably experienced early recurrence) or first-line treatment for advanced CRC between May 2016 and July 2019, and were analysed until September 2019. Factors associated with overall treatment duration from second-line treatment with FOLFIRI plus antiangiogenic drugs were explored with multivariate Cox regression analysis. The most common first-line treatments were FOLFOX (leucovorin, 5-fluorouracil, oxaliplatin) or CAPOX (capecitabine, oxaliplatin) with bevacizumab (presumed RAS-mutant CRC) and FOLFOX with panitumumab (presumed RAS-wild type CRC). The most common second-line treatments were FOLFIRI-based. Many patients did not transition to subsequent lines of therapy. For second-line treatment, antiangiogenic drugs were prescribed more often for patients with presumed RAS-mutant CRC, right-sided CRC, and independent activities of daily living (ADL). The median duration of second-line FOLFIRI plus antiangiogenic drug treatment was 4.5 months; 66.2% of patients transitioned to third-line therapy. Low body mass index and not fully independent ADL were significantly associated with shorter overall duration of antitumor drug treatment from second-line therapy. Left-sided CRC, presumed RAS-wild type CRC, previous use of oral fluoropyrimidines and use of proteinuria qualitative tests, antihypertensives, or anticholinergics during second-line therapy were significantly associated with longer treatment. Treatment of advanced CRC in Japan is consistent with both international and Japanese guidelines, but transition rates to subsequent therapies need improvement. In addition to antitumor drug treatment, better ADL, higher body mass index, management of hypertension, and proteinuria tests were associated with continuation of sequential therapy that included antiangiogenic drugs.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>33556095</pmid><doi>10.1371/journal.pone.0246160</doi><tpages>e0246160</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2021-02, Vol.16 (2), p.e0246160-e0246160 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2487424657 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Angiogenesis inhibitors Antiangiogenic agents Antiangiogenics Biology and Life Sciences Cancer Cancer therapies Chemotherapy Clinical medicine Clinical trials Colorectal cancer Colorectal carcinoma Disease Drug therapy Editing Epidermal growth factor receptors Ethics Fluorouracil Funding Gastroenterology Health care facilities Health services Homology Hospitals Leucovorin Medical research Medicine Medicine and Health Sciences Methodology Mutation Observational studies Patients Population Prescription drugs Sarcoma Surgery Visualization |
| title | Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T11%3A48%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20sequences%20of%20patients%20with%20advanced%20colorectal%20cancer%20and%20use%20of%20second-line%20FOLFIRI%20with%20antiangiogenic%20drugs%20in%20Japan:%20A%20retrospective%20observational%20study%20using%20an%20administrative%20database&rft.jtitle=PloS%20one&rft.au=Shinozaki,%20Eiji&rft.date=2021-02-08&rft.volume=16&rft.issue=2&rft.spage=e0246160&rft.epage=e0246160&rft.pages=e0246160-e0246160&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0246160&rft_dat=%3Cgale_plos_%3EA651160888%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2487424657&rft_id=info:pmid/33556095&rft_galeid=A651160888&rft_doaj_id=oai_doaj_org_article_8a6b6f8616b04dc1a6995cdd76416fb3&rfr_iscdi=true |